熱門資訊> 正文
礼来公司获得欧盟认可阿尔茨海默病药物
2025-07-25 21:01
- Despite a previous decision declining a potential marketing authorization application, Eli Lilly (NYSE:LLY) received backing from an expert panel of the EU drug regulator, the European Medicines Agency (EMA), for its Alzheimer’s treatment donanemab on Friday.
- The Indiana-based drugmaker said that the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the anti-amyloid agent for a select group of adults with early symptomatic Alzheimer's disease.
- The CHMP opinion will next be reviewed by the European Commission, which is expected to make a final decision on the company’s MAA within the next several months, the company added.
- After CHMP issued a negative opinion on the drug marketed as Kisunla in March, denying a potential marketing authorization for the monthly infusion, Eli Lilly (NYSE:LLY) requested a reevaluation of the decision in the following month.
More on Eli Lilly
- Eli Lilly: Competition Melts Away
- Eli Lilly: Still Too Pricey To Buy
- Eli Lilly Comes Out As ADA Winner
- Former biotech exec George Tidmarsh to lead key FDA drug center
- Eli Lilly's Omvoh wins Health Canada approval for Crohn’s disease
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
